Mengshi Li
I joined IDGP in Toxicology because it is “Interdisciplinary”. This program allows me the access to both pharmaceutical and environmental research. I did my first rotation in Professor Thorne’s lab, studying nanotoxicity, my second rotation with Professor Murry doing Pharmacokinetics/Pharmacodynamics studies, and my third rotation with Dr. Micahel Schultz.
By receiving comprehensive training, I hope I can start my career in risk assessment or safety evaluation of drugs and chemical products in China.
During my leisure time, I am an athletic guy. I like soccer and karate. I usually spend some time in the fitness center and the boxing club. The fitness center of this school is really cool.
Thesis Title: Melanocortin Subtype 1 Receptor (MC1R) Targeted-Radionuclide Therapy for Melanoma
Advisor: Michael K. Schultz, PhD.
Program: Ph.D.
Current Position: Principal Scientist, Director of Pipeline Discovery
Current Employer/Institution: Perspective Therapeutics
Publications from HTP Research:
Mengshi Li, Dijie Liu, Dongyoul Lee, Yinwen Cheng, Nicholas J. Baumhover, Brenna M. Marks, Edwin A. Sagastume, Zuhair K. Ballas, Frances L. Johnson, Zachary, Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma, Cancers 2021, 13(15), 3676;
Mengshi Li, Edwin A. Sagastume, Dongyoul Lee, Roy H. Larsen, Frances L. Johnson, Michael K. Schultz, 203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer, Current Medicinal Chemistry, 2020, 27, 7003-7031
